Mar 02, 2020
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2019 and Highlights Recent Corporate Updates
Feb 05, 2020
CODA Biotherapeutics Acquires Attenua and Three Clinical Stage Assets
Jan 13, 2020
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
Nov 12, 2019
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Updates
Oct 22, 2019
Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)
Aug 05, 2019
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2019 and Highlights Recent Corporate Updates
Feb 26, 2019
Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for IV Push
Feb 22, 2019
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Recent Corporate Progress
Feb 05, 2019
Heron Therapeutics Announces Retirement of Robert Rosen as President
Jan 07, 2019
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
Nov 07, 2018
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Corporate Progress
Sep 18, 2018
Chemotherapy-Induced Nausea & Vomiting (CINV) Treatment - Worldwide Markets to 2026: A $3.62 Billion Opportunity
Aug 08, 2018
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress